Charles River sweetens WuXi merger with 'synergies'

Faced with some stiff opposition from investors arrayed against a proposed $1.6 billion merger of Charles River Laboratories and China's WuXi PharmaTech, the Massachusetts-based CRO is baiting its hooks for shareholders with the promise of up to $100 million in annual "synergies" if the deal goes through.

"We are confident that our proposed combination with WuXi will create not only the world's premier early-stage contract research organization, but also significant additional shareholder value," said Charles River Chief Executive Officer James C. Foster. "Among the many metrics that support this view are the estimated revenue synergies we expect to generate from the combination."

Foster will bring that argument, and the prospect of $75 million to $100 million in potential operational savings, to the shareholders' meeting scheduled for August 5. The company already faces opposition from big investors like Jana Partners and Neuberger Berman, which see the deal as risky and sub-optimal. Charles River, meanwhile, says it also had a second request for information from the Federal Trade Commission.

- check out the release
- here's the report from Reuters

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.